CD8A and neoplasm: Strikingly, in mouse tumor models, low-dose decitabine-primed CD8+ Tex prevented the loss of JunD expression and decreased transcriptional activity following anti–PD-1 treatment, displaying stronger TCR-responsive and memory-like phenotypes, long-term proliferative capacity, and improved antitumor response.